Scinai Immunotherapeutics Ltd. highlighted its expanded contract development and manufacturing (CDMO) platform and immunology pipeline during BIO-Europe Spring 2026. The update, shared on March 18, 2026, reflects the company’s strategic focus on integrating early-stage development capabilities with advanced manufacturing services, including Active Pharmaceutical Ingredients (API).
Expanding API Development Capabilities
As part of its CDMO platform, Scinai operates a cGMP-certified small-molecule API development and manufacturing facility located in Yavne, Israel. This site supports early-stage chemistry development and small-scale API production, enabling pharmaceutical and biotech companies to advance clinical-stage programs.
The inclusion of API capabilities strengthens Scinai’s position as a service provider across the early phases of drug development, particularly for clients requiring flexible and specialized manufacturing solutions.
Strengthening Integrated CDMO Platform
The company emphasized its ability to provide an end-to-end CDMO offering, combining API development with biologics research, process development, and clinical manufacturing. This integrated approach enables seamless progression from discovery through clinical stages, reducing development timelines and improving operational efficiency.
Scinai’s platform is designed to support a wide range of therapeutic programs, particularly in immunology, where the company is actively advancing its proprietary pipeline.
Focus on Immunology and Innovation
In addition to its manufacturing capabilities, Scinai showcased progress in its NanoAb immunotherapy platform, which focuses on developing innovative treatments targeting immune-related diseases. This highlights the company’s dual strategy of advancing internal R&D while expanding its CDMO service offerings.
The combination of biologics innovation and API manufacturing capabilities positions Scinai as a versatile partner for pharmaceutical development programs.
Enhancing Global Collaboration Opportunities
Participation in BIO-Europe Spring 2026 provides Scinai with a platform to engage with global pharmaceutical and biotech companies, fostering new partnerships and business opportunities. The company aims to leverage its expanded CDMO infrastructure to attract clients seeking integrated development and manufacturing solutions.
Outlook
The update shared on March 18, 2026, highlights the growing importance of integrated CDMO platforms that combine API development with advanced therapeutic innovation. As pharmaceutical companies increasingly seek streamlined development pathways, such capabilities are expected to play a key role in accelerating drug development.
With its expanded platform, Scinai Immunotherapeutics Ltd. is strengthening its presence in the API and CDMO ecosystem while positioning itself as a partner for both early-stage development and advanced therapeutic programs.
